Phase I trial of MEDI3726, a prostate-specific membrane antigen-targeted antibody-drug conjugate, in patients with mCRPC after failure of abiraterone or enzalutamide

CONCLUSIONS: Following dose escalation, no MTD was identified. Clinical responses occurred at higher doses, but were not durable as patients had to discontinue treatment due to TRAEs.PMID:33795255 | DOI:10.1158/1078-0432.CCR-20-4528

Source: Clinical Cancer Research - April 2, 2021 Category: Cancer & Oncology Authors: Johann S de Bono Mark T Fleming Judy S Wang Richard Cathomas Manuel Selvi Miralles John Bothos Mary Jane Hinrichs Qu Zhang Peng He Marna Williams Anton I Rosenbaum Meina Liang Kapil Vashisht Song Cho Pablo Martinez Daniel P Petrylak Source Type: research